Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Tracking of Infused Mesenchymal Stem Cells in Injured Pulmonary Tissue in Atm -Deficient Mice.

Baer PC., Sann J., Duecker RP., Ullrich E., Geiger H., Bader P.

Animal Study on Systemic / IV, published in Cells (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cells (2020)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
32531978
DOI
10.3390/cells9061444

Abstract (original English)

Pulmonary failure is the main cause of morbidity and mortality in the human chromosomal instability syndrome Ataxia-telangiectasia (A-T). Major phenotypes include recurrent respiratory tract infections and bronchiectasis, aspiration, respiratory muscle abnormalities, interstitial lung disease, and pulmonary fibrosis. At present, no effective pulmonary therapy for A-T exists. Cell therapy using adipose-derived mesenchymal stromal/stem cells (ASCs) might be a promising approach for tissue regeneration. The aim of the present project was to investigate whether ASCs migrate into the injured lung parenchyma of Atm -deficient mice as an indication of incipient tissue damage during A-T. Therefore, ASCs isolated from luciferase transgenic mice (mASCs) were intravenously transplanted into Atm -deficient and wild-type mice. Retention kinetics of the cells were monitored using in vivo bioluminescence imaging (BLI) and completed by subsequent verification using quantitative real-time polymerase chain reaction (qRT-PCR). The in vivo imaging and the qPCR results demonstrated migration accompanied by a significantly longer retention time of transplanted mASCs in the lung parenchyma of Atm -deficient mice compared to wild type mice. In conclusion, our study suggests incipient damage in the lung parenchyma of Atm -deficient mice. In addition, our data further demonstrate that a combination of l

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAtaxia TelangiectasiaDisease Models, AnimalHumansLung DiseasesLung InjuryMesenchymal Stem CellsMiceMice, Transgenic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research